Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
White House: The US is monitoring a troubling Serbian military deployment along the border of Kosovo that is causing tensions.
White House: Serbia and Kosovo must fulfill their commitments and avoid taking any provocative steps.
White House spokesperson John Kirby urges Serbia to withdraw its forces from its borders with Kosovo.
Hezbollah condemns terrorist blasts carried out against worshippers in Pakistan.
NATO: Decision to deploy additional forces to address the current situation in Kosovo.
Al Mayadeen correspondent reports more than 50 people were injured when a bomb exploded in the Mastung area of the Pakistani province of Balochistan.
Iranian Intelligence Minister Esmaeil Khatib: The assassinations were scheduled to be carried out on Saturday with the aim of stirring up national and sectarian strifes in the country
Iranian Intelligence Minister Esmaeil Khatib: A series of attempts to assassinate a number of Sunni scholars, judges, and IRGC officers was thwarted
Twin shootings in Rotterdam led to multiple deaths: Dutch police
Dutch Police: Rotterdam shooter arrested

CAR T Cell Therapy reaches beyond cancer

  • By Al Mayadeen English
  • Source: Agencies
  • 24 Nov 2022 18:32
  • 1 Shares
  • x

A Penn Medicine CAR T pioneer and a doctoral student in Cell and Molecular Biology discuss the development and progress in treating certain B cell leukemia, lymphoma, and other blood cancers.

  • CAR T Cell Therapy Reaches Beyond Cancer (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)
    Researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)

Chimeric antigen receptor cells (CAR T), or engineered immune cells, have revealed the ability of personalized immunotherapies to fight blood cancers. Now, researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this progress in a commentary published today in Cell.

"We've always known that in principle, CAR T therapies could have broad applications, and it's very encouraging to see early evidence that this promise is now being realized," said June, who is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn Medicine and director of the Center for Cellular Immunotherapies at Penn's Abramson Cancer Center.

Read: Immunotherapy treatment "cures" 2 cancer patients

T cells are among the immune system's most powerful weapons. They can bind to and kill the cells they see as valid targets, including cells infected by viruses. CAR T cells are T cells that have been redirected to effectively kill specifically defined cell types, through genetic engineering.

How are CAR T therapies created?

The cells of each patient are what make CAR T therapies; they are collected from the patient's blood and engineered and multiplied in a lab before they are re-infused into the patient as a "living drug."

The first CAR T therapy, Kymriah, was developed by June and his team at Penn Medicine. It was approved by the Food and Drug Administration in 2017. There are now six FDA-approved CAR T cell therapies in the United States for six different cancers. The therapies have created a revolution in the treatment of certain B cell leukemia, lymphoma, and other blood cancers. Many patients who had little hope have now been put into long-term remission.

Since the beginning of the research, experts believed that T cells could be engineered to fight many conditions other than B cell cancers. These potential new applications are being examined by dozens of research teams around the globe.

The commentary from Baker and June comes in response to the first significant clinical report about the success resulting from these efforts: a paper in Nature Medicine by German researchers on the CAR T therapy used to fight the autoimmune disease lupus (systemic lupus erythematosus).

Lupus, according to researchers, is an obvious choice for CAR T therapy because it, too, is driven by B cells. Thus, experimental CAR T therapies can employ existing anti-B-cell designs. B cells are the immune system's antibody-producing cells, and, in lupus, B cells arise and attack the patient's own organs and tissues.

In the German study, the patients, five young adults, did not benefit from standard lupus treatments. Yet, they all went into remission and were able to stop taking their lupus drugs within three months of a single, relatively small dose of CAR T therapy, which essentially removed their existing B cells.

What was even more noticeable is that all the patients remained in remission during the follow-up period of up to a year, and unlike cancer patients, the lupus patients' B cells came back. They are naturally replenished from blood stem cells in the bone marrow.

June and Baker noted in their commentary that, although the German study's results should be confirmed with bigger studies and longer-term follow-up, they are significantly promising. They suggest that lupus could turn out to be an easier CAR T target than B-cell cancers.

"Disease-driving B cells are much less numerous in lupus," Baker said. "Thus, effective CAR T treatment of this autoimmune disease may require a much lower dose that greatly reduces the problem of immunological side-effects."

  • Cell Therapy
  • Car T
  • Cancer
  • Engineered immune cells

Most Read

Russia destroyed leopard tank in Ukraine with fully-German crew

Russia destroyed leopard tank in Ukraine with fully-German crew

  • Europe
  • 23 Sep 2023
Blinken’s ‘Variable Geometry’ for a New Cold War

Blinken’s ‘Variable Geometry’ for a New Cold War

  • Analysis
  • 24 Sep 2023
BBC from the front lines in Ukraine: It's bad, counteroffensive failed

BBC from the front lines in Ukraine: It's bad, counteroffensive failed

  • Europe
  • 28 Sep 2023
Zelensky joins Canadian Parliament’s ovation to WWII Nazi soldier

Zelensky joins Canadian Parliament’s ovation to WWII Nazi soldier

  • US & Canada
  • 25 Sep 2023

Coverage

All
Morocco & Libya Disasters

Read Next

All
BBC to restrict top hosts' social media usage
Europe

BBC to restrict hosts' social media for chiding anti-migration remarks

Germany, 'Israel'
Europe

Germany signs 'historic' deal to acquire Israeli-made Arrow 3 system

Secretary of State Antony Blinken speaks during a media briefing at the State Department, Tuesday, Aug. 15, 2023, in Washington. (AP)
Europe

'Never say never': Blinken on Biden-Putin meeting in the future

Plastic found in clouds may contaminate everything we consume
US & Canada

Microplastics in clouds cause 'plastic rainfall', infect everything

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS